Earnings Call

As TI preps its Q1 2026 earnings call, all eyes are on its performance as an indicator for the industrial, auto, and broader semiconductor sectors.

The specialty finance giant posted a stunning turnaround, leveraging tech and a hot U.S. market. Here's how it plans to deliver even more in 2026.

With its stock under pressure despite strong results, Box will use a key conference to prove its AI-powered content platform is the future of enterprise work.

As VerticalScope preps its 2025 results, investors watch if its pivot to AI and e-commerce can overcome ad market and search engine challenges.

As Revvity execs prepare for key conferences, investors will watch for clues on AI strategy, growth guidance, and margin recovery after a mixed 2025.

Investors and patients await Puma Bio's Q4 results, focusing on NERLYNX sales performance and crucial updates on its promising alisertib cancer pipeline.

As BJ’s prepares to report Q4 results, investors are watching if a pizza relaunch and new efficiencies can overcome industry-wide cost pressures.

With a strong cash position, Arcus Biosciences heads into a pivotal year as investors await critical data on its promising cancer and autoimmune pipeline.

As Home Depot prepares its year-end report, investors weigh a tough consumer market against the firm's big strategic bets on pro customers and digital tools.

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.

With strong Q3 results and key acquisitions, all eyes are on Addus HomeCare's year-end report to see if its growth momentum can be sustained.

As Omada Health preps its 2025 results, all eyes are on whether its blend of tech, human coaching, and GLP-1 support can deliver sustainable profits.

As Timbercreek Financial preps its Q4 report, investors eye dividend health and asset quality as key indicators for the broader CRE market's new cycle.

Viking Therapeutics' upcoming earnings call is about more than just financials. Investors are focused on key pipeline updates for its obesity and MASH drugs.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

ODU economists predict a stark 2026 for Virginia, citing massive federal job losses, a housing crisis, and a growing divide between the rich and poor.

Claros Mortgage Trust will report 2025 results on Feb. 18. Investors seek clarity on its strategy for navigating distress in commercial real estate.

The insurance giant beat adjusted earnings estimates on strong operational performance, even as derivative losses weighed on its reported GAAP revenue.

Amid financial scrutiny and following a major trial failure, Vistagen's upcoming Q3 update is a critical test for its novel pherine pipeline.

As Aspen Aerogels prepares its Q4 results, investors weigh a challenging 2025 against a booming aerogel market and future EV growth prospects.